Johnson & Johnson’s New Blood Cancer Drug Gets Fast Track FDA Approval
The FDA grants fast track approval to Johnson & Johnson’s TECVAYLI and DARZALEX FASPRO combination for relapsed multiple myeloma, offering improved survival outcomes.
The FDA grants fast track approval to Johnson & Johnson’s TECVAYLI and DARZALEX FASPRO combination for relapsed multiple myeloma, offering improved survival outcomes.
